APA (7th ed.) Citation

Fujii, T., Cimino‐Mathews, A., Lipkowitz, S., Lee, M., Nair, J., Solarz, B. B., . . . Lee, J. (2025). A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation. Cancer Medicine, 14(23), 1. https://doi.org/10.1002/cam4.71220

Chicago Style (17th ed.) Citation

Fujii, Takeo, et al. "A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation." Cancer Medicine 14, no. 23 (2025): 1. https://doi.org/10.1002/cam4.71220.

MLA (9th ed.) Citation

Fujii, Takeo, et al. "A Phase II Pilot Study of Anti‐PD‐L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple‐Negative Breast Cancer With or Without Germline BRCA Mutation." Cancer Medicine, vol. 14, no. 23, 2025, p. 1, https://doi.org/10.1002/cam4.71220.